T Cell CD28 Market 2026–2035 advancing with targeted immune response strategies

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Increase Is Anticipated For The T Cell Specific Surface Glycoprotein CD28 Market Over The 2026–2030 Period?

The market size for t cell specific surface glycoprotein cd28 has experienced robust growth in recent years. It is anticipated to expand from $1.62 billion in 2025 to $1.78 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 10.0%. The historical period’s growth can be primarily attributed to the early identification of cd28 as a t-cell co-stimulatory receptor, expanding immunology research, a rising prevalence of autoimmune diseases, increasing cancer research initiatives, and the limited availability of monoclonal antibody therapies.

The t cell specific surface glycoprotein cd28 market is poised for robust expansion over the coming years, with projections indicating it will attain a size of $2.58 billion by 2030, advancing at a compound annual growth rate (CAGR) of 9.7%. This anticipated growth during the forecast period is primarily attributable to several factors, including the ongoing development of lulizumab pegol and novel cd28 inhibitors, the broadening scope of preclinical and clinical trials, the integration of cd28-targeted therapies into both autoimmune and cancer treatment protocols, a surge in investment within biopharmaceutical research, and advancements in immunomodulation and monoclonal antibody engineering. Noteworthy trends anticipated in this period encompass the increasing adoption of flow cytometry and ELISA technologies, an uptick in applications across immunology and cancer research, the escalating development of innovative cd28 inhibitors and biobetters, an expansion in stem cell and autoimmune disease research efforts, and the incorporation of lulizumab pegol into preclinical and clinical studies.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27429&type=smp

Which Economic Or Industry Drivers Are Impacting The T Cell Specific Surface Glycoprotein CD28 Market?

The future expansion of the T cell-specific surface glycoprotein CD28 market is anticipated, driven by the increasing focus on personalized medicine. This medical strategy customizes treatments for individual patients, considering their unique genetic makeup, environmental influences, and lifestyle choices to achieve better results and enhance care quality. Advances in genomic technologies, allowing for exact identification of genetic differences and personalized therapies, are boosting the need for personalized medicine. By facilitating targeted immune modulation, T cell-specific surface glycoprotein CD28 plays a role in personalized medicine, leading to more accurate and potent therapies. It improves therapeutic results through fostering optimal T cell activation and refining immune responses specific to each patient. For example, data from February 2024, provided by the US-based nonprofit Personalized Medicine Coalition (PMC), indicates that the U.S. Food and Drug Administration (FDA) sanctioned 26 novel personalized medicines in 2023, marking a rise from the 12 approved in 2022. Consequently, the heightened focus on personalized medicine is a key factor propelling the expansion of the T cell-specific surface glycoprotein CD28 market.

How Is The T Cell Specific Surface Glycoprotein CD28 Market Segmented Across Key Categories?

The t cell specific surface glycoprotein cd28 market covered in this report is segmented –

1) By Type: FPT 155, FR 104, Lulizumab Pegol, Other Types

2) By Technology: Flow Cytometry, EnzymeLinked Immunosorbent Assay (ELISA), Polymerase Chain Reaction (PCR), Weste Blotting, Immunohistochemistry

3) By Distribution Channel: Direct Sales, Distributors, Ecommerce, Retail Pharmacies, Wholesalers

4) By Application: Immunology Research, Cancer Research, Autoimmune Diseases, Infectious Diseases, Stem Cell Research

5) By End-User: Hospitals, Research Laboratories, Academic Institutions, Pharmaceutical Companies, Diagnostic Laboratories

Subsegments:

1) By FPT 155: Preclinical Studies, Clinical Trials, Oncology Applications, Licensing And Partnerships

2) By FR 104: Autoimmune Disease Applications, Rheumatoid Arthritis Trials, Transplant Rejection Studies, Research Collaborations

3) By Lulizumab Pegol: Systemic Lupus Erythematosus (SLE) Studies, Immunomodulation Research, Biopharmaceutical Development, Monoclonal Antibody Engineering

4) By Other Types: Novel CD28 Inhibitors, Combination Therapies, Biosimilars And Biobetters, Emerging Research Compounds

Which Upcoming Trends Are Expected To Influence The T Cell Specific Surface Glycoprotein CD28 Market?

Leading entities within the T cell-specific surface glycoprotein CD28 market are concentrating on creating novel offerings, particularly combination immunotherapies, with the aim of improving T cell activation, bolstering anti-tumor effectiveness, and elevating patient treatment outcomes. These immunotherapies involve therapeutic strategies that merge several immune-centric methods to strengthen the body’s defensive capabilities against illness. An illustrative example is from February 2025, when Rondo Therapeutics Inc., a US-based biopharmaceutical firm, disclosed preclinical findings concerning RNDO 564, which is a new CD28 Nectin 4 costimulatory bispecific antibody developed for advanced bladder cancer. This antibody is designed to specifically activate CD28 present on T cells when it binds to tumor cells that express Nectin-4, thereby boosting T-cell-mediated destruction of tumors while simultaneously reducing unintended toxicity. The presented data showcased significant anti-tumor effectiveness in preclinical studies, providing a basis for its continued progression as a prospective treatment option for individuals suffering from metastatic urothelial carcinoma.

Who Are The Dominant Players Shaping The T Cell Specific Surface Glycoprotein CD28 Market Landscape?

Major companies operating in the t cell specific surface glycoprotein cd28 market are Gilead Sciences Inc., Johnson & Johnson, Novartis AG, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Becton Dickinson and Company, Regeneron Pharmaceuticals Inc., Bio-Techne Corporation, STEMCELL Technologies Inc., Miltenyi Biotec B.V. & Co. KG, Sino Biological Inc., Xencor Inc., ACROBiosystems Co. Ltd., Fate Therapeutics Inc., Medigene AG, Alpine Immune Sciences Inc., Adaptimmune Therapeutics plc, OSE Immunotherapeutics SA, Creative Biolabs Inc., Rondo Therapeutics Inc.

Read the full t cell specific surface glycoprotein cd28 market report here:

https://www.thebusinessresearchcompany.com/report/t-cell-specific-surface-glycoprotein-cd28-global-market-report

What Are The Top-Performing Regions Within The T Cell Specific Surface Glycoprotein CD28 Market?

North America was the largest region in the T cell-specific surface glycoprotein CD28 market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the t cell specific surface glycoprotein cd28 market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored T Cell Specific Surface Glycoprotein CD28 Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=27429&type=smp

Browse Through More Reports Similar to the Global T Cell Specific Surface Glycoprotein CD28 Market 2026, By The Business Research Company

Monitor Market Report 2026

https://www.thebusinessresearchcompany.com/report/monitor-global-market-report

Display Monitor Market Report 2026

https://www.thebusinessresearchcompany.com/report/display-monitor-global-market-report

Holter Monitor Market Report 2026

https://www.thebusinessresearchcompany.com/report/holter-monitor-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795